Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CHKA | P35790 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL209616 | 0.98 | GAA (0.63) | GAABIRC2CA2CHKAALDH1A1 | |
| SCHEMBL6963350 | 0.98 | GAA (0.63) | GAABIRC2CA2CHKAALDH1A1 | |
| Hydrochloric Acid SCHEMBL27822626 | 0.96 | GAA (0.61) | GAABIRC2CA2CHKAALDH1A1 | |
| SCHEMBL758408 | 0.92 | GAA (0.73) | GAABIRC2CA2CHKAALDH1A1 | |
| SCHEMBL655825 | 0.90 | GAA (0.69) | GAABIRC2CA2CHKAALDH1A1 | |
| SCHEMBL361321 | 0.90 | GAA (0.56) | GAABIRC2CA2CHKAALDH1A1 | |
| Hydrochloric Acid SCHEMBL8186264 | 0.88 | GAA (0.67) | GAABIRC2CA2CHKAALDH1A1 | |
| SCHEMBL20349175 | 0.85 | GAA (0.91) | GAABIRC2ALDH1A1TSHRALOX15 | |
| SCHEMBL21338467 | 0.85 | GAA (0.91) | GAABIRC2ALDH1A1TSHRALOX15 | |
| SCHEMBL3912798 | 0.85 | GAA (0.91) | GAABIRC2ALDH1A1TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3564232-B1 | BMP-SIGNAL-INHIBITING COMPOUND | RIKEN (JP) | 2022-01-26 | — | — | EP | disclosed |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| US-20210246147-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-10954216-B2 | BMP-signal-inhibiting compound | RIKEN (JP) | 2021-03-23 | — | — | US | disclosed |
| EP-3587406-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-1861376-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F. Hoffmann-Roche AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| EP-1828146-A1 | SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006097261-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211693-A1 | Cis-imidazolines | FOTOUHI NADER | 2006-09-21 | — | — | US | disclosed |
| US-20060160806-A1 | N-benzyl-N'-{(3R)-1-[(6-methylpyridin-3-yl)carbonyl]pyrrolidin-3-yl}urea | ABBVIE INC. | 2006-07-20 | — | — | US | disclosed |
| EP-1680415-A1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2006066885-A1 | SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2006-06-29 | — | — | WO | disclosed |
| WO-2005035524-A1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENSIS INHIBITORS | ABBOTT LABORATORIES (US) | 2005-04-21 | — | — | WO | disclosed |
| US-4252804-A | TRANQUILIZERS, ANTICONVULSANTS, MUSCLE RELAXANTS | METABIO-JOULLIE (FR) | 1981-02-24 | — | — | US | disclosed |
| US-4252804-A | TRANQUILIZERS, ANTICONVULSANTS, MUSCLE RELAXANTS | METABIO-JOULLIE (FR) | 1981-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954216-B2 | BMP-signal-inhibiting compound | BMP1, BMP2, BMP4 | GAA 1928/4885BIRC2 649/4885CA2 2868/4885 |
| US-20060160806-A1 | N-benzyl-N'-{(3R)-1-[(6-methylpyridin-3-yl)carbonyl]pyrrolidin-3-yl}urea | FLT4, FLT1, KDR | GAA 2412/4885BIRC2 1233/4885CA2 3575/4885 |
| US-20060211693-A1 | Cis-imidazolines | TP53, MDM2, CDC25C | GAA 2974/4885BIRC2 1610/4885CA2 994/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | GAA 456/4885BIRC2 2328/4885CA2 1522/4885 |
| US-20210246147-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | NAMPT, NAPRT, NNMT | GAA 801/4885BIRC2 1352/4885CA2 1950/4885 |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | GAA 1024/4885BIRC2 672/4885CA2 3923/4885 |
| US-20210244717-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | GAA 624/4885BIRC2 2677/4885CA2 1384/4885 |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | GAA 717/4885BIRC2 1369/4885CA2 2965/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | GAA 624/4885BIRC2 2677/4885CA2 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.